Date:10/5/2010

c and management teams and provide advice and guidance in refining our science to enable us to capitalize on our Company's promising future.  For Generex Oncology, we have brought in Dr. Craig Eagle, the head of the oncology therapeutic area of the global medical group for Pfizer, Inc., as an advisor to help us navigate through the regulatory approval process for AE37 as well to help us in our strategic partnership efforts within the pharmaceutical community.  We have also retained the consulting services of Dr. George M. Peoples, presently the Chief of Surgical Oncology at Brooke Army Medical Center in Houston, TX, a Professor of Surgery and the Director & Principal Investigator of the Cancer Vaccine Development Program at Uniformed Services University of the Health Sciences in Bethesda, MD, and the Deputy Director of the United States Military Cancer Institute (www.usmci.org).  Dr. Peoples is providing advice and assistance to us with respect to the design and implementation of a Phase III trial of the AE37 vaccine in patients with breast cancer, and acts as a liaison with the FDA regarding the clinical and regulatory development of the vaccine.  We also have engaged the services of a world-renowned independent firm used by many major pharmaceutical companies for intellectual property appraisals, to provide an appraisal of our vaccine technology platform.

As I navigate our Company through this transitional period in management, I feel it is important to communicate to our shareholders that management is committed to bringing our rich intellectual property resources to commercial fruition.  We continue to work closely with our business development consultants, including Seahawk Capital, which was instrumental in helping us regain our financial footing in 2009.  We intend to seek out unique opportunities to generate meaningful near-term revenue streams. We are confident that, together with
'/>"/>

SOURCE Generex Biotechnology Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
2. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
3. Generex Announces Presentations of Novel Vaccine Strategies
4. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
5. Generex Announces Sales Agreement with Elias Shaker & Company
6. Generex Presents Abstract at EASD Annual Meeting
7. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
11. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research